Can Fite Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.11.20	Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD) (Businesswire)
23.11.20	Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET (Businesswire)
16.11.20	Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference (Businesswire)
09.11.20	Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 (Businesswire)
13.10.20	Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 (Businesswire)
06.10.20	Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis (Businesswire)
30.09.20	Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference (Businesswire)
22.09.20	Can-Fite to Participate in Two BioPharma Partnering Conferences (Businesswire)
08.09.20	Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 (Businesswire)
31.08.20	FDA Clears Can-Fite to Commence Phase II COVID-19 Study (Businesswire)
27.08.20	Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update (Businesswire)
25.08.20	Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH (Businesswire)
20.08.20	Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET (Businesswire)
27.07.20	Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study (Businesswire)
20.07.20	Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds (Businesswire)
15.07.20	Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly (Businesswire)
06.07.20	Can-Fite Announces $3.4 Million Registered Direct Offering (Businesswire)
30.06.20	Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period (Businesswire)
10.06.20	Can-Fite Announces $8.0 Million Registered Direct Offering (Businesswire)
08.06.20	Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 (Businesswire)
04.06.20	Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer (Businesswire)
03.06.20	Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th (Businesswire)
01.06.20	Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update (Businesswire)
28.05.20	Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 (Businesswire)
21.05.20	Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office (Businesswire)
18.05.20	Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis (Businesswire)
15.05.20	Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms (Businesswire)
14.04.20	Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET (Businesswire)
13.04.20	Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately (Businesswire)
07.04.20	Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson (Businesswire)
30.03.20	Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020 (Businesswire)
27.03.20	Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update (Businesswire)
23.03.20	Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel (Businesswire)
18.03.20	Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment (Businesswire)
16.03.20	Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson (Businesswire)
11.03.20	Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD (Businesswire)
27.02.20	Pre-clinical Studies Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement (Businesswire)
24.02.20	Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications (Businesswire)
18.02.20	Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter (Businesswire)
13.02.20	Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson (Businesswire)
03.02.20	Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis (Businesswire)
16.01.20	Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects (Businesswire)
09.01.20	Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million (Businesswire)
07.01.20	Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer (Businesswire)
06.01.20	Can-Fite CEO Issues Letter to Shareholders (Businesswire)
03.01.20	New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss (Businesswire)
26.12.19	Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing (Businesswire)
09.12.19	Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial (Businesswire)
05.12.19	Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH (Businesswire)
29.11.19	Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	611.40	2.31 %	K V
CieFinRichemont	176.60	0.48 %	K V
Zurich Insur Gr	555.00	0.33 %	K V
Givaudan	3’936.00	0.28 %	K V
Logitech Intl	88.82	0.23 %	K V
Kuehne+Nagel Int	202.20	-0.49 %	K V
Swisscom	507.00	-0.59 %	K V
Nestle	77.28	-0.74 %	K V
Sonova Hldg	308.80	-2.28 %	K V
UBS Group	29.84	-6.13 %	K V

Nachrichten zu Can Fite Biopharma Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten